REGULATED PRESS RELEASE
News
-
-
-
-
-
-
REGULATED PRESS RELEASE
bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux receives 510(k) clearance and CLIA-waiver for BIOFIRE SPOTFIRE R/ST Panel, enhancing diagnostic capabilities for respiratory and sore throat infections globally -
-
REGULATED PRESS RELEASE
bioMérieux – 2023 Financial Results
-
-
REGULATED PRESS RELEASE
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux, a world leader in in vitro diagnostics, announces the appointment of two new Executive Committee members, Dr. Charles K. Cooper and Céline Roger-Dalbert, to lead Medical Affairs and Research & Development, respectively. Dr. Cooper brings extensive medical and leadership background from Siemens Healthcare Diagnostics and U.S. Food & Drug Administration, while Céline Roger-Dalbert boasts over 25 years of in vitro diagnostic experience, with significant contributions to new product launches and over 20 patent applications. Their nominations signify bioMérieux's commitment to addressing global patients' needs and driving innovation, aligning with the company's strategy. For more information, visit www.biomerieux.com.
